Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

摘要: Aspirin is proposed to be effective in stroke-prophylaxis because it completely inhibits the platelet prostanoid-pathway. In about 90% of stroke victims, increased reactivity (PR) can reduced normal range by aspirin. Twelve hours later, one third them show an enhanced PR again. These patients are called secondary aspirin non responders (SANR). this study potential pathogenetic and prognostic impact biological feature on recurrence was evaluated. Before discharge from hospital, determined 12 after oral administration 500 mg 180 aged 58 +/- 15 years; 74 were female 106 male. All had suffered a internal carotid artery territory. Patients treated with 3 x aspirin/d followed up over 24-month period. Major endpoints stroke, myocardial infarction or vascular death. On 120 showed under treatment. High test values found 60 Six lost for follow-up. Because side effects 36 (20%) enrolled discontinued medication. occurred 4 these (11%) 25 138 remaining (18.1%); 19 died consequence event during observation seen only 5 114 (4.4%) responders, but 24 out SANR (40%, p < 0.0001). It may assumed that early identification SANR's clinically useful tool classify at high risk events.